Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Recruiting 2Suspended 1

Sponsor Class

INDUSTRY 2FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3NET 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 3Neuroendocrine Tumors 1Hypoxia 1

Interventions

pembrolizumab 79Cyclophosphamide 55Specimen Handling 54Carboplatin 50fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Biopsy 38Gemcitabine 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Pemetrexed 24Cisplatin 24Ipilimumab 23Capecitabine 21Temozolomide 19Fulvestrant 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Cetuximab 18Azacitidine 18Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Ethiodized Oil × 90 days × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

NCT05842174 2026-04-16

TAQE

VA Office of Research and Development

Phase 1/2 Recruiting
93 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05435014 2026-04-14

T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma

T-ACE Medical Co., Ltd

Phase 1/2 Suspended
82 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡